Metozolv

Ingredient matches for Metozolv

Metoclopramide

Metoclopramide hydrochloride (a derivative of Metoclopramide) is reported as an ingredient of Metozolv in the following countries:

• United States

International Drug Name Search

Aerius

In the US, Aerius is a member of the drug class antihistamines and is used to treat Hay Fever and Urticaria.

Ingredient matches for Aerius

Desloratadine

Desloratadine is reported as an ingredient of Aerius in the following countries:

• Argentina


• Austria


• Bahrain


• Belgium


• Bulgaria


• Canada


• Chile


• China


• Colombia


• Costa Rica


• Croatia (Hrvatska)


• Czech Republic


• Denmark


• Dominican Republic


• El Salvador


• Finland


• France


• Georgia


• Germany


• Greece


• Guatemala


• Honduras


• Hong Kong


• Hungary


• Iceland


• Indonesia


• Israel


• Italy


• Luxembourg


• Malaysia


• Netherlands


• New Zealand


• Nicaragua


• Norway


• Oman


• Panama


• Peru


• Philippines


• Portugal


• Romania


• Russian Federation


• Serbia


• Singapore


• Slovakia


• Slovenia


• Spain


• Sweden


• Switzerland


• Taiwan


• Thailand


• Tunisia


• Turkey


• Venezuela


• Vietnam

International Drug Name Search

DayQuil

Generic Name: acetaminophen, dextromethorphan, and pseudoephedrine (a SEET a MIN oh fen, DEX troe me THOR fan, SOO doe ee FED rin)

Brand Names: Alka-Seltzer Plus Flu Liquigels, Comtrex Non-Drowsy, DayQuil, Dayquil Liquicaps, Daytime Cold, Non-Drowsy Daytime, Robitussin Honey Flu Non-Drowsy, Theraflu (pseudoephedrine) Daytime Severe Cold, Theraflu Severe Cold & Congestion Non-Drowsy, Triaminic Cough & Sore Throat (pseudoephedrine), Triaminic Softchew Throat Pain and Cough, Triaminic Softchews Cough & Sore Throat (pseudoephedrine)

What is DayQuil (acetaminophen, dextromethorphan, and pseudoephedrine)?

Acetaminophen is a pain reliever and fever reducer.

Dextromethorphan is a cough suppressant. It affects the signals in the brain that trigger cough reflex.

Pseudoephedrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).

The combination of acetaminophen, dextromethorphan, and pseudoephedrine is used to treat headache, fever, body aches, cough, stuffy nose, and sinus congestion caused by allergies, the common cold, or the flu.

This medicine will not treat a cough that is caused by smoking, asthma, or emphysema.

Acetaminophen, dextromethorphan, and pseudoephedrine may also be used for purposes not listed in this medication guide.

What is the most important information I should know about DayQuil (acetaminophen, dextromethorphan, and pseudoephedrine)?

Do not take more of this medication than is recommended. An overdose of acetaminophen can damage your liver or cause death. Do not take this medication without a doctor's advice if you have ever had alcoholic liver disease (cirrhosis) or if you drink more than 3 alcoholic beverages per day. Do not use this medicine if you have untreated or uncontrolled diseases such as glaucoma, asthma or COPD, high blood pressure, heart disease, coronary artery disease, or overactive thyroid. Avoid drinking alcohol. It may increase your risk of liver damage while you are taking acetaminophen. Do not use this medicine if you have used an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects. Ask a doctor or pharmacist before using any other cold, allergy, pain, or sleep medication. Acetaminophen (sometimes abbreviated as APAP) is contained in many combination medicines. Taking certain products together can cause you to get too much acetaminophen which can lead to a fatal overdose. Check the label to see if a medicine contains acetaminophen or APAP.

What should I discuss with my healthcare provider before taking DayQuil (acetaminophen, dextromethorphan, and pseudoephedrine)?

Do not take this medication without a doctor's advice if you have ever had alcoholic liver disease (cirrhosis) or if you drink more than 3 alcoholic beverages per day. You may not be able to take medicine that contains acetaminophen. Do not use this medicine if you have untreated or uncontrolled diseases such as glaucoma, asthma or COPD, high blood pressure, heart disease, coronary artery disease, or overactive thyroid. Do not use this medicine if you have used an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.

Ask a doctor or pharmacist if it is safe for you to take acetaminophen, dextromethorphan, and pseudoephedrine if you have:

• 
  

  liver disease, cirrhosis, or a history of alcoholism;

  
  


• 
  

  diabetes;

  
  


• 
  

  glaucoma;

  
  


• 
  

  diabetes;

  
  


• 
  

  epilepsy or other seizure disorder;

  
  


• 
  

  enlarged prostate or urination problems;

  
  


• 
  

  pheochromocytoma (an adrenal gland tumor); or

  
  


• 
  

  cough with mucus, or cough caused by emphysema or chronic bronchitis.

  
  

It is not known whether acetaminophen, dextromethorphan, and pseudoephedrine will harm an unborn baby. Do not use this medicine without a doctor's advice if you are pregnant. Acetaminophen, dextromethorphan, and pseudoephedrine may pass into breast milk and may harm a nursing baby. Decongestants may also slow breast milk production. Do not use this medicine without a doctor's advice if you are breast-feeding a baby.

Artificially sweetened cold medicine may contain phenylalanine. If you have phenylketonuria (PKU), check the medication label to see if the product contains phenylalanine.

How should I take DayQuil (acetaminophen, dextromethorphan, and pseudoephedrine)?

Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. This medicine is usually taken only for a short time until your symptoms clear up.

Do not take more of this medication than is recommended. An overdose of acetaminophen can damage your liver or cause death. Do not give this medication to a child younger than 4 years old. Always ask a doctor before giving cough or cold medicine to a child. Death can occur from the misuse of cough or cold medicine in very young children.

Measure liquid medicine with a special dose measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose measuring device, ask your pharmacist for one.

The chewable tablet must be chewed thoroughly before you swallow it.

Dissolve one packet of the powder in at least 4 ounces of water. Stir this mixture and drink all of it right away.

Do not take for longer than 7 days in a row. Stop taking the medicine and call your doctor if you still have a fever after 3 days of use, you still have pain after 7 days (or 5 days if treating a child), if your symptoms get worse, or if you have a skin rash, ongoing headache, or any redness or swelling.

If you need surgery or medical tests, tell the surgeon or doctor ahead of time if you have taken this medicine within the past few days. Store at room temperature away from moisture and heat. Do not allow liquid medicine to freeze.

What happens if I miss a dose?

Since this medicine is taken when needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222. An overdose of acetaminophen can be fatal.

The first signs of an acetaminophen overdose include loss of appetite, nausea, vomiting, stomach pain, sweating, and confusion or weakness. Later symptoms may include pain in your upper stomach, dark urine, and yellowing of your skin or the whites of your eyes.

Overdose symptoms may also include severe forms of some of the side effects listed in this medication guide.

What should I avoid while taking DayQuil (acetaminophen, dextromethorphan, and pseudoephedrine)?

Ask a doctor or pharmacist before using any other cold, allergy, pain, or sleep medication. Acetaminophen (sometimes abbreviated as APAP) is contained in many combination medicines. Taking certain products together can cause you to get too much acetaminophen which can lead to a fatal overdose. Check the label to see if a medicine contains acetaminophen or APAP. This medication may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. Avoid drinking alcohol. It may increase your risk of liver damage while you are taking acetaminophen.

DayQuil (acetaminophen, dextromethorphan, and pseudoephedrine) side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. chest pain, fast, slow, or uneven heart rate; Stop using this medication and call your doctor at once if you have any of these serious side effects:

• 
  

  chest pain, fast, slow, or uneven heart rate;

  
  


• 
  

  severe dizziness, feeling like you might pass out;

  
  


• 
  

  mood changes, confusion, hallucinations;

  
  


• 
  

  tremor, seizure (convulsions);

  
  


• 
  

  fever;

  
  


• 
  

  urinating less than usual or not at all;

  
  


• 
  

  nausea, pain in your upper stomach, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of your skin or eyes); or

  
  


• 
  

  nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).

  
  


• 
  

  dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, chest pain, uneven heartbeats, seizure).

  
  

Less serious side effects may include:

• 
  

  dizziness, weakness;

  
  


• 
  

  mild headache;

  
  


• 
  

  mild nausea, diarrhea, upset stomach;

  
  


• 
  

  dry mouth, nose, or throat;

  
  


• 
  

  feeling nervous, restless, irritable, or anxious; or

  
  


• 
  

  sleep problems (insomnia).

  
  

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect DayQuil (acetaminophen, dextromethorphan, and pseudoephedrine)?

Ask a doctor or pharmacist if it is safe for you to take this medicine if you are also using any of the following drugs:

• 
  

  leflunomide (Arava);

  
  


• 
  

  tapentadol (Nucynta);

  
  


• 
  

  an antibiotic, antifungal medicine, sulfa drug, or tuberculosis medicine;

  
  


• 
  

  an antidepressant;

  
  


• 
  

  birth control pills or hormone replacement therapy;

  
  


• 
  

  blood pressure medication;

  
  


• 
  

  cancer medicine;

  
  


• 
  

  cholesterol-lowering medications such as Lipitor, Niaspan, Zocor, Vytorin, and others;

  
  


• 
  

  gout or arthritis medications (including gold injections);

  
  


• 
  

  HIV/AIDS medication;

  
  


• 
  

  medicines to treat psychiatric disorders;

  
  


• 
  

  migraine headache medicine;

  
  


• 
  

  an NSAID such as Advil, Aleve, Arthrotec, Cataflam, Celebrex, Indocin, Motrin, Naprosyn, Treximet, Voltaren, others; or

  
  


• 
  

  seizure medication.

  
  

This list is not complete and other drugs may interact with acetaminophen, dextromethorphan, and pseudoephedrine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

More DayQuil resources

• DayQuil Side Effects (in more detail)
• DayQuil Use in Pregnancy & Breastfeeding
• DayQuil Drug Interactions
• 0 Reviews for DayQuil - Add your own review/rating

• DayQuil Liquid MedFacts Consumer Leaflet (Wolters Kluwer)

Compare DayQuil with other medications

• Cold Symptoms

Where can I get more information?

• Your pharmacist can provide more information about acetaminophen, dextromethorphan, and pseudoephedrine.

See also: DayQuil side effects (in more detail)

Credanil

Credanil may be available in the countries listed below.

Ingredient matches for Credanil

Carbidopa

Carbidopa is reported as an ingredient of Credanil in the following countries:

• Romania

Carbidopa monohydrate (a derivative of Carbidopa) is reported as an ingredient of Credanil in the following countries:

• Cyprus

Levodopa

Levodopa is reported as an ingredient of Credanil in the following countries:

• Cyprus


• Romania

International Drug Name Search

Dextrostat

dextroamphetamine sulfate

Dosage Form: tablets

Warning

AMPHETAMINES HAVE A HIGH POTENTIAL FOR ABUSE. ADMINISTRATION OF AMPHETAMINES FOR PROLONGED PERIODS OF TIME MAY LEAD TO DRUG DEPENDENCE AND MUST BE AVOIDED. PARTICULAR ATTENTION SHOULD BE PAID TO THE POSSIBILITY OF SUBJECTS OBTAINING AMPHETAMINES FOR NON-THERAPEUTIC USE OR DISTRIBUTION TO OTHERS, AND THE DRUGS SHOULD BE PRESCRIBED OR DISPENSED SPARINGLY.

MISUSE OF AMPHETAMINES MAY CAUSE SUDDEN DEATH AND SERIOUS CARDIOVASCULAR ADVERSE EVENTS.

Dextrostat Description

Dextrostat® (dextroamphetamine sulfate) is the dextro isomer of the compound d,l-amphetamine sulfate, a sympathomimetic amine of the amphetamine group. Chemically, dextroamphetamine is d-alpha-methyl-phenethylamine, and is present in all forms of Dextrostat® as the neutral sulfate. It has a chemical formula of (C9H13N)2•H2SO4 and a molecular weight of 368.50.

Structural Formula:

Each tablet, for oral administration, contains dextroamphetamine sulfate USP, 5 mg or 10 mg. Each tablet also contains the following inactive ingredients: acacia, corn starch, lactose monohydrate, magnesium stearate, sucrose. 10 mg tablet contains sodium starch glycolate. 5 mg and 10 mg tablets contain FD&C Yellow #5 (tartrazine).

Dextrostat - Clinical Pharmacology

Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. Peripheral actions include elevations of systolic and diastolic blood pressures and weak bronchodilator and respiratory stimulant action.

There is neither specific evidence that clearly establishes the mechanism whereby amphetamines produce mental and behavioral effects in children, nor conclusive evidence regarding how these effects relate to the condition of the central nervous system.

Pharmacokinetics

The single ingestion of two 5 mg tablets by healthy volunteers produced an average peak dextroamphetamine blood level of 29.2 ng/mL at 2 hours post-administration. The average half-life was 10.25 hours. The average urinary recovery was 45% in 48 hours.

Indications and Usage for Dextrostat

Dextroamphetamine sulfate tablets are indicated in:

1. Narcolepsy.


2. Attention Deficit Disorder with Hyperactivity: As an integral part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.

Contraindications

Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma.

Agitated states.

Patients with a history of drug abuse.

During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result).

Warnings

Serious Cardiovascular Events

Sudden Death in Patients with Pre-existing Structural Cardiac Abnormalities or Other Serious Heart Problems

Children and Adolescents

Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. Although some serious heart problems alone carry an increased risk of sudden death, stimulant products generally should not be used in children or adolescents with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug.

Adults

Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses for ADHD. Although the role of stimulants in these adult cases is also unknown, adults have a greater likelihood than children of having serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems. Adults with such abnormalities should also generally not be treated with stimulant drugs (see CONTRAINDICATIONS).

Hypertension and other Cardiovascular Conditions

Stimulant medications cause a modest increase in average blood pressure (about 2-4 mmHg) and average heart rate (about 3-6 bpm), and individuals may have larger increases. While the mean changes alone would not be expected to have short-term consequences, all patients should be monitored for larger changes in heart rate and blood pressure. Caution is indicated in treating patients whose underlying medical conditions might be compromised by increases in blood pressure or heart rate, e.g., those with pre-existing hypertension, heart failure, recent myocardial infarction, or ventricular arrhythmia (see CONTRAINDICATIONS).

Assessing Cardiovascular Status in Patients being Treated with Stimulant Medications

Children, adolescents, or adults who are being considered for treatment with stimulant medications should have a careful history (including assessment for a family history of sudden death or ventricular arrhythmia) and physical exam to assess for the presence of cardiac disease, and should receive further cardiac evaluation if findings suggest such disease (e.g. electrocardiogram and echocardiogram). Patients who develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease during stimulant treatment should undergo a prompt cardiac evaluation.

Psychiatric Adverse Events

Pre-Existing Psychosis

Administration of stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with pre-existing psychotic disorder.

Bipolar Illness

Particular care should be taken in using stimulants to treat ADHD patients with comorbid bipolar disorder because of concern for possible induction of mixed/manic episode in such patients. Prior to initiating treatment with a stimulant, patients with comorbid depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression.

Emergence of New Psychotic or Manic Symptoms

Treatment emergent psychotic or manic symptoms, e.g., hallucinations, delusional thinking, or mania in children and adolescents without prior history of psychotic illness or mania can be caused by stimulants at usual doses. If such symptoms occur, consideration should be given to a possible causal role of the stimulant, and discontinuation of treatment may be appropriate. In a pooled analysis of multiple short-term, placebo-controlled studies, such symptoms occurred in about 0.1% (4 patients with events out of 3482 exposed to methylphenidate or amphetamine for several weeks at usual doses) of stimulant-treated patients compared to 0 in placebo-treated patients.

Aggression

Aggressive behavior or hostility is often observed in children and adolescents with ADHD, and has been reported in clinical trials and the postmarketing experience of some medications indicated for the treatment of ADHD. Although there is no systematic evidence that stimulants cause aggressive behavior or hostility, patients beginning treatment for ADHD should be monitored for the appearance of, or worsening of, aggressive behavior or hostility.

Long-Term Suppression of Growth

Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or non-medication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and non-medication treated children over 36 months (to the ages of 10 to 13 years), suggests that consistently medicated children (i.e., treatment for 7 days per week throughout the year) have a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this period of development. Published data are inadequate to determine whether chronic use of amphetamines may cause a similar suppression of growth, however, it is anticipated that they likely have this effect as well. Therefore, growth should be monitored during treatment with stimulants, and patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted.

Seizures

There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizure, in patients with prior EEG abnormalities in absence of seizures, and very rarely, in patients without a history of seizures and no prior EEG evidence of seizures. In the presence of seizures, the drug should be discontinued.

Visual Disturbance

Difficulties with accommodation and blurring of vision have been reported with stimulant treatment.

Precautions

General:

The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.

These tablets contain FD&C Yellow No.5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. Although the overall incidence of FD&C Yellow No.5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

Information for Patients: Amphetamines may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or vehicles; the patient should therefore be cautioned accordingly.

Prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with dextroamphetamine and should counsel them in its appropriate use. A patient Medication Guide is available for Dextrostat®. The prescriber or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have. The complete text of the Medication Guide is reprinted at the end of this document.

Drug Interactions:

Acidifying agents -Gastro-intestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines. Urinary acidifying agents (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion. Both groups of agents lower blood levels and efficacy of amphetamines.

Adrenergic blockers -Adrenergic blockers are inhibited by amphetamines.

Alkalinizing agents-Gastro-intestinal alkalinizing agents (sodium bicarbonate, etc.) increase absorption of amphetamines. Urinary alkalinizing agents (acetazolamide, some thiazides) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion. Both groups of agents increase blood levels and therefore potentiate the actions of amphetamines.

Antidepressants, tricyclic- Amphetamines may enhance the activity of tricyclic or sympathomimetic agents; d-amphetamine with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated.

MAO inhibitors -MAOI antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism. This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; this can cause headaches and other signs of hypertensive crisis. A variety of neurological toxic effects and malignant hyperpyrexia can occur, sometimes with fatal results.

Antihistamines -Amphetamines may counteract the sedative effect of antihistamines.

Antihypertensives -Amphetamines may antagonize the hypotensive effects of antihypertensives.

Chlorpromazine -Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.

Ethosuximide -Amphetamines may delay intestinal absorption of ethosuximide.

Haloperidol -Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.

Lithium carbonate -The stimulatory effects of amphetamines may be inhibited by lithium carbonate.

Meperidine -Amphetamines potentiate the analgesic effect of meperidine.

Methenamine therapy -Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.

Norepinephrine -Amphetamines enhance the adrenergic effect of norepinephrine.

Phenobarbital -Amphetamines may delay intestinal absorption of phenobarbital; co-administration of phenobarbital may produce a synergistic anticonvulsant action.

Phenytoin -Amphetamines may delay intestinal absorption of phenytoin; co-administration of phenytoin may produce a synergistic anticonvulsant action.

Propoxyphene -In cases of propoxyphene overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.

Veratrum alkaloids -Amphetamines inhibit the hypotensive effect of veratrum alkaloids.

Drug/Laboratory Test Interactions:

Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening. Amphetamines may interfere with urinary steroid determinations.

Carcinogenesis/Mutagenesis:

Mutagenicity studies and long-term studies in animals to determine the carcinogenic potential of Dextrostat® (dextroamphetamine sulfate) have not been performed.

Pregnancy - Teratogenic Effects:

Pregnancy Category C. Dextroamphetamine has been shown to have embryotoxic and teratogenic effects when administered to A/Jax mice and C57BL mice in doses approximately 41 times the maximum human dose. Embryotoxic effects were not seen in New Zealand white rabbits given the drug in doses 7 times the human dose nor in rats given 12.5 times the maximum human dose. While there are no adequate and well-controlled studies in pregnant women, there has been one report of severe congenital bony deformity, tracheo-esophageal fistula, and anal atresia (Vater association) in a baby born to a woman who took dextroamphetamine sulfate with lovastatin during the first trimester of pregnancy. Dextroamphetamine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nonteratogenic Effects:

Infants born to mothers dependent on amphetamines have an increased risk of premature delivery and low birth weight. Also, these infants may experience symptoms of withdrawal as demonstrated by dysphoria, including agitation, and significant lassitude.

Nursing Mothers:

Amphetamines are excreted in human milk. Mothers taking amphetamines should be advised to refrain from nursing.

Pediatric Use:

Long-term effects of amphetamines in pediatric patients have not been well established. Amphetamines are not recommended for use in pediatric patients under 3 years of age with Attention Deficit Disorder with Hyperactivity described under INDICATIONS AND USAGE.

Clinical experience suggests that in psychotic pediatric patients, administration of amphetamines may exacerbate symptoms of behavior disturbance and thought disorder.

Amphetamines have been reported to exacerbate motor and phonic tics and Tourette's syndrome. Therefore, clinical evaluation for tics and Tourette's syndrome in pediatric patients and their families should precede use of stimulant medications.

Data are inadequate to determine whether chronic administration of amphetamines may be associated with growth inhibition; therefore, growth should be monitored during treatment.

Drug treatment is not indicated in all cases of Attention Deficit Disorder with Hyperactivity and should be considered only in light of the complete history and evaluation of the pediatric patient. The decision to prescribe amphetamines should depend on the physician's assessment of the chronicity and severity of the pediatric patient's symptoms and their appropriateness for his/her age. Prescription should not depend solely on the presence of one or more of the behavioral characteristics.

When these symptoms are associated with acute stress reactions, treatment with amphetamines is usually not indicated.

Adverse Reactions

Cardiovascular: Palpitations, tachycardia, elevation of blood pressure. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use.

Central Nervous System: Psychotic episodes at recommended doses (rare), overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome.

Gastrointestinal: Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances. Anorexia and weight loss may occur as undesirable effects.

Allergic: Urticaria.

Endocrine: Impotence, changes in libido.

Drug Abuse and Dependence

Dextroamphetamine sulfate tablets are a Schedule II controlled substance.

Amphetamines have been extensively abused. Tolerance, extreme psychological dependence, and severe social disability have occurred. There are reports of patients who have increased the dosage to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG.

Manifestations of chronic intoxication with amphetamines include severe dermatoses, marked insomnia, irritability, hyperactivity, and personality changes. The most severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia. This is rare with oral amphetamines.

Overdosage

Individual patient response to amphetamines varies widely. While toxic symptoms occasionally occur as an idiosyncrasy at doses as low as 2 mg, they are rare with doses of less than 15 mg: 30 mg can produce severe reactions, yet doses of 400 to 500 mg are not necessarily fatal.

In rats, the oral LD50 of dextroamphetamine sulfate is 96.8 mg/kg.

Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rhabdomyolysis, rapid respiration, hyperpyrexia, confusion, assaultiveness, hallucinations, panic states.

Fatigue and depression usually follow the central stimulation.

Cardiovascular effects include arrhythmias, hypertension or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning is usually preceded by convulsions and coma.

TREATMENT- Consult with a Certified Poison Control Center for up-to-date guidance and advice. Management of acute amphetamine intoxication is largely symptomatic and includes gastric lavage, administration of activated charcoal, administration of a cathartic, and sedation. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendation in this regard. Acidification of the urine increases amphetamine excretion, but is believed to increase risk of acute renal failure if myoglobinuria is present. If acute severe hypertension complicates amphetamine overdosage, administration of intravenous phentolamine has been suggested. However, a gradual drop in blood pressure will usually result when sufficient sedation has been achieved.

Chlorpromazine antagonizes the central stimulant effects of amphetamines and can be used to treat amphetamine intoxication.

Dextrostat Dosage and Administration

Amphetamines should be administered at the lowest effective dosage and dosage should be individually adjusted. Late evening doses should be avoided because of the resulting insomnia.

Narcolepsy: Usual dose is 5 to 60 mg per day in divided doses, depending on the individual patient response.

Narcolepsy seldom occurs in pediatric patients under 12 years of age; however, when it does, Dextrostat® (dextroamphetamine sulfate) may be used. The suggested initial dose for patients aged 6 to 12 is 5 mg daily; daily dose may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. In patients 12 years of age and older, start with 10 mg daily, daily dosage may be raised in increments of 10 mg at weekly intervals until an optimal response is obtained. If bothersome adverse reactions appear (e.g., insomnia or anorexia), dosage should be reduced. Give first dose on awakening; additional doses (1 or 2) at intervals of 4 to 6 hours.

Attention Deficit Disorder with Hyperactivity: Not recommended for pediatric patients under 3 years of age.

In pediatric patients from 3 to 5 years of age, start with 2.5 mg daily, by tablet; daily dosage may be raised in increments of 2.5 mg at weekly intervals until optimal response is obtained.

In pediatric patients 6 years of age and older, start with 5 mg once or twice daily; daily dosage may be raised in increments of 5 mg at weekly intervals until optimal response is obtained. Only in rare cases will it be necessary to exceed a total of 40 mg per day.

Give first dose on awakening: additional doses (1 or 2) at intervals of 4 to 6 hours.

Where possible, drug administration should be interrupted occasionally to determine if there is a recurrence of behavioral symptoms sufficient to require continued therapy.

How is Dextrostat Supplied

Dextrostat® (dextroamphetamine sulfate) Tablets are available as follows:

5 mg Yellow, Round, Scored Tablet debossed "RP" on one side and "51" on the other side.

NDC #: 54092-448-01 for 100s

10 mg Yellow, Round, Double-Scored tablet debossed "RP" on one side and "52" on the other side.

NDC #: 54092-452-01 for 100s

Dispense in a tight container as defined in the USP.

Store at 25° C (77° F) excursions 15-30° C (59-86° F). [See USP Controlled Room Temperature]

DEA Order Form Required.

Pharmacist: Medication Guide to be dispensed to patients.

Manufactured for:

Shire US Inc.

725 Chesterbrook Blvd.

Wayne, PA 19087

Made in USA

©2007, Shire US Inc.

448 0107 005

Rev. 10/07 005344

MEDICATION GUIDE

Dextrostat® (DEX-troe-stat) CII

(dextroamphetamine sulfate) Tablets

Read the Medication Guide that comes with Dextrostat® before you or your child starts taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your doctor about your or your child's treatment with Dextrostat®.

What is the most important information I should know about Dextrostat®? The following have been reported with use of Dextrostat® and other stimulant medicines. 1. Heart-related problems: • sudden death in patients who have heart problems or heart defects • stroke and heart attack in adults • increased blood pressure and heart rate Tell your doctor if you or your child have any heart problems, heart defects, high blood pressure, or a family history of these problems. Your doctor should check you or your child carefully for heart problems before starting Dextrostat®. Your doctor should check you or your child's blood pressure and heart rate regularly during treatment with Dextrostat® Call your doctor right away if you or your child has any signs of heart problems such as chest pain, shortness of breath, or fainting while taking Dextrostat®. 2. Mental (Psychiatric) problems: All Patients • new or worse behavior and thought problems • new or worse bipolar illness • new or worse aggressive behavior or hostility Children and Teenagers • new psychotic symptoms (such as hearing voices, believing things that are not true, are suspicious) or new manic symptoms Tell your doctor about any mental problems you or your child have, or about a family history of suicide, bipolar illness, or depression. Call your doctor right away if you or your child has any new or worsening mental symptoms or problems while taking Dextrostat®, especially seeing or hearing things that are not real, believing things that are not real, or are suspicious.

What Is Dextrostat®?

Dextrostat® is a central nervous system stimulant prescription medicine. It is used for the treatment of Attention Deficit Hyperactivity Disorder(ADHD). Dextrostat® may help increase attention and decrease impulsiveness and hyperactivity in patients with ADHD.

Dextrostat® should be used as a part of a total treatment program for ADHD that may include counseling or other therapies.

Dextrostat® is also used in the treatment of a sleep disorder called narcolepsy.

Dextrostat® is a federally controlled substance (CII) because it can be abused or lead to dependence. Keep Dextrostat® in a safe place to prevent misuse and abuse. Selling or giving away Dextrostat® may harm others, and is against the law. Tell your doctor if you or your child have (or have a family history of) ever abused or been dependent on alcohol, prescription medicines or street drugs.

Who should not take Dextrostat®?

Dextrostat® should not be taken if you or your child:

• Have heart disease or hardening of the arteries

• Have moderate to severe high blood pressure

• Have hyperthyroidism

• Have an eye problem called glaucoma

• Are very anxious, tense, or agitated

• Have a history of drug abuse

• Are taking or have taken within the past 14 days an anti-depression medicine called a monoamine oxidase inhibitor or MAOI.

• Is sensitive to, allergic to, or had a reaction to other stimulant medicines

Dextrostat® is not recommended for use in children less than 3 years old.

Dextrostat® may not be right for you or your child. Before starting Dextrostat® tell your or your child's doctor about all health conditions (or a family history of) including:

• Heart problems, heart defects, high blood pressure

• Mental problems including psychosis, mania, bipolar illness, or depression

• Tics or Tourette's syndrome

• Thyroid problems

• Seizures or have had an abnormal brain wave test (EEG)

Tell your doctor if you or your child is pregnant, planning to become pregnant, or breastfeeding.

Can Dextrostat® be taken with other medicines?

Tell your doctor about all of the medicines that you or your child takes including prescription and non-prescription medicines, vitamins, and herbal supplements. Dextrostat® and some medicines may interact with each other and cause serious side effects. Sometimes the doses of other medicines will need to be adjusted while taking Dextrostat®.

Your doctor will decide whether Dextrostat® can be taken with other medicines.

Especially tell your doctor if you or your child takes:

• Anti-depression medicines including MAOIs

• Blood pressure medicines

• Antacids

• Seizure medicines

Know the medicines that you or your child takes. Keep a list of your medicines with you to show your doctor and pharmacist.

Do not start any new medicine while taking Dextrostat® without talking to your doctor first.

How should Dextrostat® be taken?

• Take Dextrostat® exactly as prescribed. Your doctor may adjust the dose until it is right for you or your child.

• Dextrostat® tablets are usually taken two to three times a day. The first dose is usually taken in the morning. One or two more doses may be taken during the day, 4 to 6 hours apart.

• From time to time, your doctor may stop Dextrostat® treatment for a while to check ADHD symptoms.

• Your doctor may do regular checks of the blood, heart, and blood pressure while taking Dextrostat®. Children should have their height and weight checked often while taking Dextrostat®. Dextrostat® treatment may be stopped if a problem is found during these check-ups.

If you or your child takes too much Dextrostat® or overdoses, call your doctor or poison control center right away, or get emergency treatment.

What are possible side effects of Dextrostat®?

See "What is the most important information I should know about Dextrostat®?" for information on reported heart and mental problems.

Other serious side effects include:

• Slowing of growth (height and weight) in children

• Seizures, mainly in patients with a history of seizures

• Eyesight changes or blurred vision

Common side effects include:

• Fast heart beat

• Tremors

• Trouble sleeping

• Stomach upset

• Dry mouth

• Decreased appetite

• Headache

• Dizziness

• Weight loss

Dextrostat® may affect you or your child's ability to drive or do other dangerous activities.

Talk to your doctor if you or your child has side effects that are bothersome or do not go away.

This is not a complete list of possible side effects. Ask your doctor or pharmacist for more information.

How should I store Dextrostat®?

• Store Dextrostat® Tablets in a safe place at room temperature, 59 to 86° F (15 to 30° C).

• Keep Dextrostat® and all medicines out of the reach of children.

General information about Dextrostat®

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use Dextrostat® for a condition for which it was not prescribed. Do not give Dextrostat® to other people, even if they have the same condition. It may harm them and it is against the law.

This Medication Guide summarizes the most important information about Dextrostat®. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about Dextrostat® that was written for healthcare professionals. For more information about Dextrostat®, you may also contact Shire Pharmaceuticals (the maker of Dextrostat®) at 1-800-828-2088 or visit the website at http://www.shire.com

What are the ingredients in Dextrostat®?

Active Ingredients: dextroamphetamine sulphate

Inactive Ingredients: acacia, corn starch, lactose monohydrate, magnesium stearate, sucrose. 10 mg tablet contains sodium starch glycolate. 5 mg and 10 mg tablets contain FD&C Yellow #5 (tartrazine).

Manufactured for Shire US Inc., Wayne, PA 19087.

©2007 Shire US Inc.

Rev. 10/07

448 0110 002 005343

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Dextrostat  dextroamphetamine sulfate  tablet

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 54092-448 Route of Administration ORAL DEA Schedule CII

INGREDIENTS Name (Active Moiety) Type Strength dextroamphetamine sulfate (Dextroamphetamine) Active 5 MILLIGRAM  In 1 TABLET acacia Inactive   corn starch Inactive   lactose monohydrate Inactive   magnesium stearate Inactive   sucrose Inactive   tartrazine Inactive

Product Characteristics Color yellow Score 2 pieces Shape ROUND Size 9mm Flavor Imprint Code RP;51 Contains          Coating false Symbol false

Packaging # NDC Package Description Multilevel Packaging 1 54092-448-01 100 TABLET In 1 BOTTLE None

Dextrostat  dextroamphetamine sulfate  tablet

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 54092-452 Route of Administration ORAL DEA Schedule CII

INGREDIENTS Name (Active Moiety) Type Strength dextroamphetamine sulfate (Dextroamphetamine) Active 10 MILLIGRAM  In 1 TABLET acacia Inactive   corn starch Inactive   lactose monohydrate Inactive   magnesium stearate Inactive   sucrose Inactive   sodium starch glycolate Inactive   tartrazine Inactive

Product Characteristics Color yellow Score 2 pieces Shape ROUND Size 10mm Flavor Imprint Code RP;52 Contains          Coating false Symbol false

Packaging # NDC Package Description Multilevel Packaging 1 54092-452-01 100 TABLET In 1 BOTTLE None

Revised: 07/2008Shire US Inc.

More Dextrostat resources

• Dextrostat Side Effects (in more detail)
• Dextrostat Dosage
• Dextrostat Use in Pregnancy & Breastfeeding
• Drug Images
• Dextrostat Drug Interactions
• Dextrostat Support Group
• 2 Reviews for Dextrostat - Add your own review/rating

• Dextrostat Advanced Consumer (Micromedex) - Includes Dosage Information


• Dextrostat Concise Consumer Information (Cerner Multum)


• Dextroamphetamine Monograph (AHFS DI)


• Dexedrine MedFacts Consumer Leaflet (Wolters Kluwer)


• Dexedrine Spansule Sustained-Release Capsules MedFacts Consumer Leaflet (Wolters Kluwer)


• Liquadd Solution MedFacts Consumer Leaflet (Wolters Kluwer)

Compare Dextrostat with other medications

• ADHD
• Narcolepsy
• Sexual Dysfunction, SSRI Induced

Daliresp

Pronunciation: roe-FLUE-mi-last
Generic Name: Roflumilast
Brand Name: Daliresp

Daliresp is used for:

Reducing the risk of flare-ups and worsened breathing problems in certain patients with severe chronic obstructive pulmonary disease (COPD).

Daliresp is a phosphodiesterase type 4 (PDE4) inhibitor. Exactly how it works is not known.

Do NOT use Daliresp if:

• you are allergic to any ingredient in Daliresp


• you have moderate to severe liver problems


• you are taking carbamazepine, hydantoins (eg, phenytoin), phenobarbital, primidone, rifamycins (eg, rifampin), or St. John's wort

Contact your doctor or health care provider right away if any of these apply to you.

Before using Daliresp:

Some medical conditions may interact with Daliresp. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

• if you are pregnant, planning to become pregnant, or are breast-feeding


• if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement


• if you have allergies to medicines, foods, or other substances


• if you have a history of liver problems, mental or mood problems (eg, depression), or suicidal thoughts or behaviors

Some MEDICINES MAY INTERACT with Daliresp. Tell your health care provider if you are taking any other medicines, especially any of the following:

• Certain birth control pills (eg, containing gestodene or ethinyl estradiol), cimetidine, enoxacin, erythromycin, fluvoxamine, itraconazole, or ketoconazole because they may increase the risk of Daliresp's side effects


• Carbamazepine, hydantoins (eg, phenytoin), phenobarbital, primidone, rifamycins (eg, rifampin), or St. John's wort because they may decrease Daliresp's effectiveness

This may not be a complete list of all interactions that may occur. Ask your health care provider if Daliresp may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Daliresp:

Use Daliresp as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Daliresp comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Daliresp refilled.


• Take Daliresp by mouth with or without food.


• If you miss a dose of Daliresp, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Daliresp.

Important safety information:

• Daliresp may cause dizziness. These effects may be worse if you take it with alcohol or certain medicines. Use Daliresp with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.


• Daliresp will not stop sudden, severe breathing problems. Be sure to carry a short-acting bronchodilator inhaler with you at all times to treat any breathing problems that may occur between doses of Daliresp (eg, severe or sudden onset of wheezing or shortness of breath). If you have any questions about which medicines stop sudden, severe breathing problems, check with your doctor or pharmacist.


• Patients who take Daliresp may be at increased risk of mental or mood changes, including suicidal thoughts or actions. The risk may be greater in patients who have had these problems in the past. Watch patients who take Daliresp closely. Contact the doctor at once if new, worsened, or sudden symptoms, such as depressed mood, anxious behavior, trouble sleeping, or any unusual change in mood or behavior occur. Contact the doctor right away if any signs of suicidal thoughts or actions occur.


• Daliresp may cause weight loss in some patients. You may need regular weight checks while taking Daliresp. Discuss any questions or concerns with your doctor.


• Daliresp should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed.


• PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of taking Daliresp while you are pregnant. It is not known if Daliresp is found in breast milk. Do not breast-feed while taking Daliresp.

Possible side effects of Daliresp:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Back pain; decreased appetite; diarrhea; dizziness; flu-like symptoms; headache; mild weight loss; nausea.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); decreased, difficult, or painful urination; irregular heartbeat; new or worsening mental or mood problems (eg, anxiety, depression); severe or persistent stomach or back pain; severe or unexplained weight loss; suicidal thoughts or behaviors; tremor; trouble sleeping.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Daliresp side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include cool, moist, and unusually pale skin; dizziness, light-headedness, or fainting; headache; irregular heartbeat.

Proper storage of Daliresp:

Store Daliresp at room temperature, between 68 and 77 degrees F (20 and 25 degrees C). Brief storage at temperatures between 59 and 86 degrees F (15 and 30 degrees C) is permitted. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Daliresp out of the reach of children and away from pets.

General information:

• If you have any questions about Daliresp, please talk with your doctor, pharmacist, or other health care provider.


• Daliresp is to be used only by the patient for whom it is prescribed. Do not share it with other people.


• If your symptoms do not improve or if they become worse, check with your doctor.


• Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Daliresp. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Daliresp resources

• Daliresp Side Effects (in more detail)
• Daliresp Use in Pregnancy & Breastfeeding
• Daliresp Drug Interactions
• Daliresp Support Group
• 6 Reviews for Daliresp - Add your own review/rating

• Daliresp Prescribing Information (FDA)


• Daliresp Advanced Consumer (Micromedex) - Includes Dosage Information


• Daliresp Consumer Overview


• Roflumilast Professional Patient Advice (Wolters Kluwer)

Compare Daliresp with other medications

• COPD
• COPD, Maintenance

Aminosalicylic Acid

In the US, Aminosalicylic Acid (aminosalicylic acid systemic) is a member of the drug class aminosalicylates and is used to treat Tuberculosis - Active and Tuberculosis - Resistant.

US matches:

• Aminosalicylic Acid Controlled-Release Granules Packet


• Aminosalicylic Acid

Scheme

USP

ATC (Anatomical Therapeutic Chemical Classification)

J04AA01

CAS registry number (Chemical Abstracts Service)

0000065-49-6

Chemical Formula

C7-H7-N-O3

Molecular Weight

153

Therapeutic Category

Antitubercular agent

Chemical Names

4-Aminosalicylic acid

Benzoic acid, amino-2-hydroxy-

Foreign Name

• 4-Aminosalicylsäure (German)

Generic Names

• P.A.S. (OS: DCF)
• Para-aminosalicylic acid (IS)
• Pasalicylum (IS)
• Aminosalicylic Acid (PH: USP 32)
• Calcium (aminosalicylate de) (OS: DCF)
• Calcium para-aminosalicylate (OS: JAN)
• Aminosalicylic Acid, Calcium salt (IS)
• Calcium PAS (IS)
• Nippas Calcium (IS)
• Calcium Para-aminosalicylate (PH: JP XV)
• Aminosalicylate Sodium (OS: USAN)
• Sodium (aminosalicylate de) (OS: DCF)
• 4-ASA-Na (IS)
• para-Aminosalicylsaures Natrium-2-Wasser (IS: ASK)
• Parasal Sodium (IS)
• Sodium para-aminosalicylate (IS)
• Sodium PAS (IS)
• UNII-S38B9W6AXW (IS)
• Aminosalicylate Sodium (PH: USP 32)
• Natrii aminosalicylas dihydricus (PH: Ph. Eur. 6)
• Sodium Aminosalicylate Dihydrate (PH: BP 2010, Ph. Eur. 6)

Brand Names

• Novo 5-ASA
  Novopharm, Canada



• PAS
  Koçak, Turkey



• Paser
  Jacobus, Latvia; Jacobus, United States



• Nippas Calcium
  Tanabe Mitsubishi, Japan



• Pas Calcium
  Pei Li, Taiwan



• Pas-Fatol N
  Riemser, Germany



• Pask-Akri
  Akrihin, Russian Federation



• PASS natrija sals
  Olainfarm, Latvia



• Quadrasa
  Norgine, France; Norgine, Luxembourg; Norgine Pharma, Slovakia



• Salf-Pas
  Salf, Italy

International Drug Name Search

Glossary

DCF	Dénomination Commune Française
IS	Inofficial Synonym
JAN	Japanese Accepted Name
OS	Official Synonym
PH	Pharmacopoeia Name
USAN	United States Adopted Name
USP	Pharmacopoeia of the United States

Click for further information on drug naming conventions and International Nonproprietary Names.

Troxevasin

Troxevasin may be available in the countries listed below.

Ingredient matches for Troxevasin

Troxerutin

Troxerutin is reported as an ingredient of Troxevasin in the following countries:

• Bulgaria


• Estonia


• Georgia


• Latvia


• Lithuania


• Romania


• Russian Federation

International Drug Name Search

Mainheart

Mainheart may be available in the countries listed below.

Ingredient matches for Mainheart

Bisoprolol

Bisoprolol fumarate (a derivative of Bisoprolol) is reported as an ingredient of Mainheart in the following countries:

• Japan

International Drug Name Search

Navispare

Navispare may be available in the countries listed below.

UK matches:

• Navispare Tablets (Goldshield plc) (SPC)

Ingredient matches for Navispare

Amiloride

Amiloride hydrochloride dihydrate (a derivative of Amiloride) is reported as an ingredient of Navispare in the following countries:

• United Kingdom

Cyclopenthiazide

Cyclopenthiazide is reported as an ingredient of Navispare in the following countries:

• United Kingdom

International Drug Name Search

Glossary

SPC	Summary of Product Characteristics (UK)

Click for further information on drug naming conventions and International Nonproprietary Names.